Gland Pharma announced an investment of over Rs 400 crore at Genome Valley to enhance their existing facility to manufacture biologicals, biosimilars, antibodies and recombinant insulin.

The expanded facility will aid in employment generation for more than 500 numbers of qualified, skilled and semi-skilled workforce. The company established their biopharmaceutical facility in February 2022 at Genome Valley with an investment of Rs 300 crores to manufacture vaccines, biologicals, biosimilars, antibodies and others. Over 200 employees have been recruited in the facility.

The announcement was made during Industries Minister KT Rama Rao’s meeting with Gland Pharma Managing Director and Chief Executive Officer Srinivas Sadu.